secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001213900-24-102265
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharmaceuticals Reports Productive FDA Type C Meeting for Mino-Lok Phase 3 Program
--------------------------------------------------------------------------------

- Citius Pharma held a constructive in-person Type C meeting with the FDA on November 25, 2024, regarding its Phase 3 Mino-Lok trial for catheter-related bloodstream infections.
- The FDA provided clear, actionable guidance on clinical efficacy and safety data, supporting a pathway to a future New Drug Application (NDA) submission.
- Chairman and CEO Leonard Mazur stated the Agency's comprehensive feedback provides a strong framework for completing remaining steps toward an NDA.
- Mino-Lok, if approved, could reduce healthcare costs and improve outcomes by salvaging central venous catheters instead of removing them.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024102265/0001213900-24-102265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024102265/ea0222478-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-102265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer